House Dust Mite Allergy Treatment Market: By Treatment (Antihistamine, Immunotherapy, and Others), By Drug Type (Prescription Drugs and Over-The-Counter Drugs), By Route of Administration (Oral, Nasal Drugs, and Others), and By Geography

House Dust Mite Allergy Treatment Market size was valued at USD 2.1 billion in 2023 and is projected to grow at 14.5% CAGR over the forecast years to reach USD 5.4 billion by 2030. The House Dust Mite Allergy Treatment Market refers to the segment of the healthcare industry focused on products and therapies designed to manage and treat allergies caused by house dust mites (HDM). House dust mites are tiny organisms found in house dust, and their allergens can trigger allergic reactions in susceptible individuals. These allergies can manifest as respiratory issues like asthma and allergic rhinitis (hay fever). House dust mite allergies are prevalent worldwide, affecting a significant portion of the population, especially in regions with high humidity and where house dust mites thrive. House dust mite allergy causes symptoms such as hay fever, cough, runny nose, and itchy red watery eyes.

The growth of the global market for treating house dust mite allergies is primarily fueled by the growing prevalence of allergic conditions linked to dust mites, increasing demand for immunological products, rising investments from both private and government sectors to develop pharmaceutical manufacturing capabilities, and expanding research and development efforts to create anti-allergy medications. According to a chief medical officer at Medscape Education in 2020, approximately 20 million Americans suffer from house dust mite allergies. Furthermore, a study published in the Journal of Scientific Report in March 2022 identified house dust mites as a prominent cause of airway allergic diseases. However, the rise in hygiene practices reduces the occurrence of house dust mite allergy, which, in turn, is expected to restrict the market growth.

House Dust Mite Allergy Treatment Market Recent Developments:

• In June 2022. Allergy Therapeutics, a UK-based biotech company, announced the approval of its clinical trial application in Spain to advance its next-generation house dust mite allergy vaccine into phase I clinical development.
• In February 2018, Stallergenes Greer and Shionogi & Co., Ltd. obtained marketing approval for Actair, an allergy immunotherapy drug designed to treat allergic rhinitis caused by house dust mites in Japan. Stallergenes Greer collaborated with Shionogi & Co., Ltd., and submitted a New Drug Application in January 2017.